Cargando…

Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab‐paclitaxel in pancreatic cancer

Detalles Bibliográficos
Autores principales: Zhang, Zheng, Ji, Shunrong, Hu, Qiangsheng, Zhuo, Qifeng, Liu, Wei, Xu, Wenyan, Liu, Wensheng, Liu, Mengqi, Ye, Zeng, Fan, Guixiong, Xu, Xiaowu, Yu, Xianjun, Qin, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387784/
https://www.ncbi.nlm.nih.gov/pubmed/34459132
http://dx.doi.org/10.1002/ctm2.398
_version_ 1783742514211061760
author Zhang, Zheng
Ji, Shunrong
Hu, Qiangsheng
Zhuo, Qifeng
Liu, Wei
Xu, Wenyan
Liu, Wensheng
Liu, Mengqi
Ye, Zeng
Fan, Guixiong
Xu, Xiaowu
Yu, Xianjun
Qin, Yi
author_facet Zhang, Zheng
Ji, Shunrong
Hu, Qiangsheng
Zhuo, Qifeng
Liu, Wei
Xu, Wenyan
Liu, Wensheng
Liu, Mengqi
Ye, Zeng
Fan, Guixiong
Xu, Xiaowu
Yu, Xianjun
Qin, Yi
author_sort Zhang, Zheng
collection PubMed
description
format Online
Article
Text
id pubmed-8387784
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-83877842021-08-31 Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab‐paclitaxel in pancreatic cancer Zhang, Zheng Ji, Shunrong Hu, Qiangsheng Zhuo, Qifeng Liu, Wei Xu, Wenyan Liu, Wensheng Liu, Mengqi Ye, Zeng Fan, Guixiong Xu, Xiaowu Yu, Xianjun Qin, Yi Clin Transl Med Letter to Editor John Wiley and Sons Inc. 2021-08-26 /pmc/articles/PMC8387784/ /pubmed/34459132 http://dx.doi.org/10.1002/ctm2.398 Text en © 2021 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Letter to Editor
Zhang, Zheng
Ji, Shunrong
Hu, Qiangsheng
Zhuo, Qifeng
Liu, Wei
Xu, Wenyan
Liu, Wensheng
Liu, Mengqi
Ye, Zeng
Fan, Guixiong
Xu, Xiaowu
Yu, Xianjun
Qin, Yi
Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab‐paclitaxel in pancreatic cancer
title Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab‐paclitaxel in pancreatic cancer
title_full Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab‐paclitaxel in pancreatic cancer
title_fullStr Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab‐paclitaxel in pancreatic cancer
title_full_unstemmed Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab‐paclitaxel in pancreatic cancer
title_short Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab‐paclitaxel in pancreatic cancer
title_sort improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab‐paclitaxel in pancreatic cancer
topic Letter to Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387784/
https://www.ncbi.nlm.nih.gov/pubmed/34459132
http://dx.doi.org/10.1002/ctm2.398
work_keys_str_mv AT zhangzheng improvedtumorcontrolwithantiangiogenictherapyaftertreatmentwithgemcitabineandnabpaclitaxelinpancreaticcancer
AT jishunrong improvedtumorcontrolwithantiangiogenictherapyaftertreatmentwithgemcitabineandnabpaclitaxelinpancreaticcancer
AT huqiangsheng improvedtumorcontrolwithantiangiogenictherapyaftertreatmentwithgemcitabineandnabpaclitaxelinpancreaticcancer
AT zhuoqifeng improvedtumorcontrolwithantiangiogenictherapyaftertreatmentwithgemcitabineandnabpaclitaxelinpancreaticcancer
AT liuwei improvedtumorcontrolwithantiangiogenictherapyaftertreatmentwithgemcitabineandnabpaclitaxelinpancreaticcancer
AT xuwenyan improvedtumorcontrolwithantiangiogenictherapyaftertreatmentwithgemcitabineandnabpaclitaxelinpancreaticcancer
AT liuwensheng improvedtumorcontrolwithantiangiogenictherapyaftertreatmentwithgemcitabineandnabpaclitaxelinpancreaticcancer
AT liumengqi improvedtumorcontrolwithantiangiogenictherapyaftertreatmentwithgemcitabineandnabpaclitaxelinpancreaticcancer
AT yezeng improvedtumorcontrolwithantiangiogenictherapyaftertreatmentwithgemcitabineandnabpaclitaxelinpancreaticcancer
AT fanguixiong improvedtumorcontrolwithantiangiogenictherapyaftertreatmentwithgemcitabineandnabpaclitaxelinpancreaticcancer
AT xuxiaowu improvedtumorcontrolwithantiangiogenictherapyaftertreatmentwithgemcitabineandnabpaclitaxelinpancreaticcancer
AT yuxianjun improvedtumorcontrolwithantiangiogenictherapyaftertreatmentwithgemcitabineandnabpaclitaxelinpancreaticcancer
AT qinyi improvedtumorcontrolwithantiangiogenictherapyaftertreatmentwithgemcitabineandnabpaclitaxelinpancreaticcancer